Burt Wealth Advisors Acquires New Shares in Thermo Fisher Scientific Inc. (NYSE:TMO)

Burt Wealth Advisors bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 331 shares of the medical research company’s stock, valued at approximately $205,000.

Several other large investors also recently modified their holdings of TMO. CFO4Life Group LLC acquired a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at about $234,000. Empowered Funds LLC lifted its stake in Thermo Fisher Scientific by 53.3% in the 1st quarter. Empowered Funds LLC now owns 7,704 shares of the medical research company’s stock valued at $4,478,000 after acquiring an additional 2,677 shares in the last quarter. Hilltop National Bank acquired a new position in Thermo Fisher Scientific during the 1st quarter worth approximately $487,000. Nelson Capital Management LLC grew its stake in shares of Thermo Fisher Scientific by 3.7% during the 1st quarter. Nelson Capital Management LLC now owns 8,422 shares of the medical research company’s stock worth $4,895,000 after acquiring an additional 298 shares in the last quarter. Finally, Forsta AP Fonden lifted its position in shares of Thermo Fisher Scientific by 10.5% in the first quarter. Forsta AP Fonden now owns 92,770 shares of the medical research company’s stock worth $53,919,000 after purchasing an additional 8,800 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded down $1.59 on Friday, reaching $554.30. 308,196 shares of the company’s stock were exchanged, compared to its average volume of 1,455,037. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a twelve month low of $437.26 and a twelve month high of $627.88. The company has a fifty day moving average of $596.33 and a 200-day moving average of $583.80. The company has a market capitalization of $212.02 billion, a price-to-earnings ratio of 34.85, a PEG ratio of 3.70 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. The firm had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company’s revenue was up .2% on a year-over-year basis. During the same quarter last year, the company earned $5.69 EPS. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the transaction, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at $9,333,946.08. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the transaction, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the transaction, the executive vice president now owns 16,663 shares of the company’s stock, valued at $9,333,946.08. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,150 shares of company stock valued at $10,094,925. Company insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TMO. Bernstein Bank lifted their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research note on Tuesday, October 22nd. Royal Bank of Canada lowered their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Sanford C. Bernstein cut their price target on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating for the company in a research note on Thursday, October 24th. Finally, Raymond James upped their target price on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $649.33.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.